Nick Morrell, MBBS, MD
Co-Founder & Chief Executive Officer
Dr. Nick Morrell, MD, MBBA, is Co-Founder and Chief Executive Officer of Morphogen-IX and a physician scientist in the field of Pulmonary Arterial Hypertension (PAH). Nick is also a Professor of Medicine at the University of Cambridge and has published over 250 papers on PAH, receiving a Lifetime Achievement Award from the European Respiratory Society in 2019. He is a Fellow of the UK Academy of Medical Sciences, emeritus National Institute of Health Research UK Senior Investigator and Honorary Fellow of the Faculty of Pharmaceutical Medicine.
Nick’s academic research focuses on the genetic and molecular mechanisms underlying PAH. He leads UK and international studies to identify novel genetic drivers of PAH. Nick’s research revealed that deficient bone morphogenetic protein signaling (BMP) is a central causal pathway in PAH, which led directly to the concept behind Morphogen-IX’s approach.
Nick works closely with his co-founders, Dr. Wei Li and Dr. Paul Upton, both at the University of Cambridge.
Read more here about Morphogen-IX